Doctors Gave AI Chatbots a Cognitive Test. Their Diagnosis? Early Dementia.
Neurologists hope this tongue-in-cheek study will spark serious conversations about AI's limitations and the benefits of a human touch in medicine.
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer’s Agitation “CALMA” and Expands Recruitment Strategy
POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease ...
Discovery of molecular mechanisms offers new targets for Huntington's treatment
A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing ...
Science Daily4h
Potential new therapeutic targets for Huntington's disease
A research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other neurodegenerative disorders such as ...
Study reveals how long people with dementia live after diagnosis
Medics have revealed how long a person can expect to live after being diagnosed with dementia. Survival rates range between ...
New Scientist9hOpinion
The neuroscientist using music to help treat Alzheimer's and more
We have long suspected that music has restorative qualities, but Daniel Levitin is now providing rigorous evidence that it ...
J&J's Posdinemab Granted FDA Fast Track Designation For Alzheimer's Treatment
Johnson & Johnson (JNJ) announced that the FDA has granted Fast Track designation to its Posdinema, a monoclonal antibody ...
Johnson & Johnson Gets FDA Fast-Track Designation for Posdinemab in Alzheimer's
The New Brunswick, N.J., pharmaceutical giant said posdinemab has shown potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid from treated Alzheimer's patients, and in ...